Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhi...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2024-05, Vol.90 (5), p.1365-1370 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1370 |
|---|---|
| container_issue | 5 |
| container_start_page | 1365 |
| container_title | British journal of clinical pharmacology |
| container_volume | 90 |
| creator | Shapiro, Samantha B. Yin, Hui Yu, Oriana H. Y. Azoulay, Laurent |
| description | We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident lung cancer. Crude incidence rates were 0.94 per 1000 person‐years among 69 675 SGLT‐2 inhibitor users followed for a median of 2.4 years and 1.45 per 1000 person‐years among 151 495 DPP‐4 inhibitor users followed for a median of 3.7 years. No reduced short‐term risk of lung cancer was observed among SGLT‐2 inhibitor users after weighting (HR 0.96, 95% CI 0.77–1.21). Further research with a longer follow‐up period may be warranted. |
| doi_str_mv | 10.1111/bcp.16039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2956683014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2956683014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3209-3cacb050837aaaa50c603939f4dd36955f685f3162226d6e124fdf4c53c952d33</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60fsJkuoeEmVQALWkWM7rSGJg-2o6o5P4Bv5Elxa2HE3oxkdXWkOAKcYjXHMpJTdGHNE8z0wxJSzhGDC9sEQUcQTRhgegCPvXxHCFHN2CAY0S6dThrMhaJ6sMn3z9fG5qHtpvYbSBida31kXtIt3Ak27NKUJ1nkoWgXDUkNn_Bu0Faz7dgGlaKV2UDQ2Lp0IRrfBw5UJSxjWnYYEKiNKHbQ_BgeVqL0-2c0ReLm5fp7dJfOH2_vZ5TyRlKA8oVLIEjGU0amIYUhunqN5lSpFec5YxTNWxV8IIVxxjUlaqSqVjMqcEUXpCJxveztn33vtQ9EYL3Vdi1bb3hckZ5xnFOE0ohdbVDrrvdNV0TnTCLcuMCo2dotot_ixG9mzXW1fNlr9kb86IzDZAitT6_X_TcXV7HFb-Q3T6IYL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956683014</pqid></control><display><type>article</type><title>Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Shapiro, Samantha B. ; Yin, Hui ; Yu, Oriana H. Y. ; Azoulay, Laurent</creator><creatorcontrib>Shapiro, Samantha B. ; Yin, Hui ; Yu, Oriana H. Y. ; Azoulay, Laurent</creatorcontrib><description>We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident lung cancer. Crude incidence rates were 0.94 per 1000 person‐years among 69 675 SGLT‐2 inhibitor users followed for a median of 2.4 years and 1.45 per 1000 person‐years among 151 495 DPP‐4 inhibitor users followed for a median of 3.7 years. No reduced short‐term risk of lung cancer was observed among SGLT‐2 inhibitor users after weighting (HR 0.96, 95% CI 0.77–1.21). Further research with a longer follow‐up period may be warranted.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.16039</identifier><identifier>PMID: 38477518</identifier><language>eng</language><publisher>England</publisher><subject>Aged ; Cohort Studies ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Female ; Humans ; Hypoglycemic Agents - adverse effects ; Incidence ; lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - epidemiology ; Male ; Middle Aged ; pharmacoepidemiology ; Proportional Hazards Models ; Risk Factors ; SGLT‐2 inhibitor ; Sodium-Glucose Transporter 2 Inhibitors - adverse effects ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; type 2 diabetes ; United Kingdom - epidemiology</subject><ispartof>British journal of clinical pharmacology, 2024-05, Vol.90 (5), p.1365-1370</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3209-3cacb050837aaaa50c603939f4dd36955f685f3162226d6e124fdf4c53c952d33</cites><orcidid>0000-0002-7957-508X ; 0000-0001-5162-3556</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.16039$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.16039$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38477518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shapiro, Samantha B.</creatorcontrib><creatorcontrib>Yin, Hui</creatorcontrib><creatorcontrib>Yu, Oriana H. Y.</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><title>Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident lung cancer. Crude incidence rates were 0.94 per 1000 person‐years among 69 675 SGLT‐2 inhibitor users followed for a median of 2.4 years and 1.45 per 1000 person‐years among 151 495 DPP‐4 inhibitor users followed for a median of 3.7 years. No reduced short‐term risk of lung cancer was observed among SGLT‐2 inhibitor users after weighting (HR 0.96, 95% CI 0.77–1.21). Further research with a longer follow‐up period may be warranted.</description><subject>Aged</subject><subject>Cohort Studies</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Incidence</subject><subject>lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>pharmacoepidemiology</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>SGLT‐2 inhibitor</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - adverse effects</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><subject>type 2 diabetes</subject><subject>United Kingdom - epidemiology</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60fsJkuoeEmVQALWkWM7rSGJg-2o6o5P4Bv5Elxa2HE3oxkdXWkOAKcYjXHMpJTdGHNE8z0wxJSzhGDC9sEQUcQTRhgegCPvXxHCFHN2CAY0S6dThrMhaJ6sMn3z9fG5qHtpvYbSBida31kXtIt3Ak27NKUJ1nkoWgXDUkNn_Bu0Faz7dgGlaKV2UDQ2Lp0IRrfBw5UJSxjWnYYEKiNKHbQ_BgeVqL0-2c0ReLm5fp7dJfOH2_vZ5TyRlKA8oVLIEjGU0amIYUhunqN5lSpFec5YxTNWxV8IIVxxjUlaqSqVjMqcEUXpCJxveztn33vtQ9EYL3Vdi1bb3hckZ5xnFOE0ohdbVDrrvdNV0TnTCLcuMCo2dotot_ixG9mzXW1fNlr9kb86IzDZAitT6_X_TcXV7HFb-Q3T6IYL</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Shapiro, Samantha B.</creator><creator>Yin, Hui</creator><creator>Yu, Oriana H. Y.</creator><creator>Azoulay, Laurent</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7957-508X</orcidid><orcidid>https://orcid.org/0000-0001-5162-3556</orcidid></search><sort><creationdate>202405</creationdate><title>Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes</title><author>Shapiro, Samantha B. ; Yin, Hui ; Yu, Oriana H. Y. ; Azoulay, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3209-3cacb050837aaaa50c603939f4dd36955f685f3162226d6e124fdf4c53c952d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Cohort Studies</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Incidence</topic><topic>lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>pharmacoepidemiology</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>SGLT‐2 inhibitor</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - adverse effects</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</topic><topic>type 2 diabetes</topic><topic>United Kingdom - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shapiro, Samantha B.</creatorcontrib><creatorcontrib>Yin, Hui</creatorcontrib><creatorcontrib>Yu, Oriana H. Y.</creatorcontrib><creatorcontrib>Azoulay, Laurent</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shapiro, Samantha B.</au><au>Yin, Hui</au><au>Yu, Oriana H. Y.</au><au>Azoulay, Laurent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2024-05</date><risdate>2024</risdate><volume>90</volume><issue>5</issue><spage>1365</spage><epage>1370</epage><pages>1365-1370</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident lung cancer. Crude incidence rates were 0.94 per 1000 person‐years among 69 675 SGLT‐2 inhibitor users followed for a median of 2.4 years and 1.45 per 1000 person‐years among 151 495 DPP‐4 inhibitor users followed for a median of 3.7 years. No reduced short‐term risk of lung cancer was observed among SGLT‐2 inhibitor users after weighting (HR 0.96, 95% CI 0.77–1.21). Further research with a longer follow‐up period may be warranted.</abstract><cop>England</cop><pmid>38477518</pmid><doi>10.1111/bcp.16039</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7957-508X</orcidid><orcidid>https://orcid.org/0000-0001-5162-3556</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2024-05, Vol.90 (5), p.1365-1370 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2956683014 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Aged Cohort Studies Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - adverse effects Female Humans Hypoglycemic Agents - adverse effects Incidence lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - epidemiology Male Middle Aged pharmacoepidemiology Proportional Hazards Models Risk Factors SGLT‐2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use type 2 diabetes United Kingdom - epidemiology |
| title | Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T10%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors%20and%20the%20risk%20of%20lung%20cancer%20among%20patients%20with%20type%202%20diabetes&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Shapiro,%20Samantha%20B.&rft.date=2024-05&rft.volume=90&rft.issue=5&rft.spage=1365&rft.epage=1370&rft.pages=1365-1370&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.16039&rft_dat=%3Cproquest_cross%3E2956683014%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2956683014&rft_id=info:pmid/38477518&rfr_iscdi=true |